Table 1 Epidemiological characteristics, treatment and follow-up of enrolled patients

Extrauterine LGESS, n (%)

9 (16.1)

Mitotic activity < 5 per 10 high power field, n (%)

45 (80.4)

Immunohistochemical staining, n (%)

 Positive estrogen receptor

51 (91.1)

 Positive progesterone receptor

50 (89.3)

DFS after first treatment (months), median (range)

34.7 (5–188)

Ages at diagnosis of recurrence (years), median (range)

43.3 (17–70)

Extrapelvic recurrence, n (%)

23 (41.1)

Symptomatic recurrence, n (%)

23 (41.1)

Repeated surgeries for first recurrence, n (%)

50 (89.3)

 With residual lesions, n/n (%)

3/50 (6.0)

Chemotherapy for recurrence, n (%)

17 (30.4)

Radiotherapy for recurrence, n (%)

18 (32.1)

Hormone treatment for recurrence, n (%)

26 (46.4)

Fertility sparing

 Fertility sparing after first treatment, n (%)

9 (16.1)

 Fertility sparing after first recurrence, n (%)

6 (10.7)

Ovarian preservation

 Ovarian preservation after first treatment, n (%)

35 (62.5)

 Ovarian preservation after first recurrence, n (%)

9 (16.1)

Loss to follow-up, n (%)

13 (23.2)

Repeated recurrence, n/n (%)

30/43 (69.8)

 PFI after last treatment for first recurrence (months), median (range)

18.3 (1–121)

Death, n/n (%)

12/43 (27.9)

 OS after diagnosis of first recurrence (months), median (range)

43.6 (3–349)